Investor Presentaiton

Darovasertib Clinical & Commercial Strategy in Uveal Melanoma Indication High Unmet Need and Multiple First-Line Opportunities across the Patient Journey Indication is the Diagnostic: +95% of UM patients harbor GNAQ/GNA11 or upstream activating mutation of PKC-signaling, enabling Broad Applicability of Darovasertib in this Indication HLA-A2-Negative (~60-65% of UM / MUM)** No FDA Approved Therapies* Neoadjuvant UM Daro Phase 2 Enucleation Define Accelerated Approval Daro Phase 2 Radiation Define Accelerated Approval Path Path No FDA Approved Therapies* Uveal Melanoma Patient Journey Adjuvant UM First-Line MUM Pretreated MUM Daro Phase 2 Define Accelerated Approval Path Therapies* No FDA Approved Daro + Crizo Registrational Trial Accelerated Approval Daro + Crizo Target NCCN / Compendia Listing HLA-A2-Positive (~35-40% of UM / MUM)** Target Treatment Duration Target Clinical Endpoints Annual Incidence US/EU** Total Prevalence US/EU** >6 months Eye & Vision Preservation >6 months Relapse Free Survival mPFS + ~3 months ORR, mPFS, MOS mPFS + ~3 months ORR, MPFS, MOS ~8-10k ~100k ~8-10k ~100k ~4-5k ~14k FDA Orphan Drug Designation in Uveal Melanoma+ 21 *No FDA approved systemic therapies in multiple UM and MUM indications across the patient journey **IDEAYA data: HLA-A2-positive and HLA-A2-negative prevalence in MUM based on IDEAYA clinical trial data; US/EU MUM annual incidence and total prevalence based on market research analysis Orphan Drugs benefit from certain tax credits and may be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act IDEAVA BIOSCIENCES

View entire presentation